Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
50 Cards in this Set
- Front
- Back
What two characteristics of the immune system can be predicted to potentially produce injury? |
1) The primary recognition receptors (TCR, Ig) are generated relatively randomly (has capacity to make self-receptors)
2) Most of the major effector mechanisms (enzymes, free radicals, etc.) are non-specific (can harm host) |
|
Type I hypersensitivity (anaphylactic type) (Definition) |
A rapidly developing immunologic reaction occurring within minutes after the combination of an antigen with antibody bound to mast cells (tissue) or basophils (blood) in individuals previously sensitized by prior exposure to the antigen |
|
Can a type 1 hypersensitivity reaction occur in response to a first-time exposure to an antigen? |
No, the individual must have been previously sensitized |
|
Which class of Ig is responsible for type I hypersensitivity? |
IgE |
|
When are IgE Ab produced in favor of IgG Ab? |
When helper T cells of the Th2 type are favored over the Th1 type |
|
What cytokine, secreted by Th2 cells, is responsible for B cell isotype switching to IgE? |
IL-4 |
|
What is a basophil? |
Essentially a circulating mast cell |
|
How do IgE antibodies adhere to mast cells and basophils? |
Via Fc receptors, leaving the Fab portion available for binding with antigen |
|
What happens when an individual is re-exposed to a IgE-specific antigen? |
Degranulation of mast cells and basophils, releasing primary and secondary mediators that produce inflammation |
|
What is an example of a primary mediator released by mast cells and basophils? |
Histamine |
|
What are the characteristics of a primary mediator released by mast cells and basophils? |
Fast-acting (minutes)
Short-lived |
|
What are some examples of secondary mediators released from mast cells and basophils? |
Leukotrienes C4, D4, and E4 and prostaglandins (all derived from arachidonic acid) |
|
What are the characteristics of secondary mediators released form mast cells and basophils? |
Slow-acting (hours)
Long-lived |
|
What are the general effects of primary and secondary mediators released from mast cells and basophils? |
Vasodilation, increased vascular permeability, cellular infiltration, and bronchial smooth muscle spasm
ACUTE INFLAMMATORY RESPONSE |
|
What is the key in determining the severity of a type I hypersensitivity reaction? |
Antigen location |
|
Type I hypersensitivity reactions can range from ____ to ____ anaphylaxis |
Local to systemic |
|
Type II hypersensitivity (Definition) |
An immunological reaction mediated by antibodies directed toward antigens present on the surface of cells or other tissue components; includes complement dependent reactions, antibody dependent cell-mediated cytotoxicity (ADCC), and antibody-mediated cellular dysfunction |
|
What Ig isotypes are responsible for type II hypersensitivity? |
IgG, IgM, IgA |
|
Complement dependent reactions (Definition) |
When an antibody, most commonly IgG or IgM, attaches to a self-cell surface and activates the complement cascade |
|
Clinical examples of complement dependent reactions |
Tranfusion reactions
Erythroblastosis fetalis
Autoimmune hemolytic anemia
Pemphigus vulgaris |
|
Antibody dependent cell-mediated cytotoxicity (ADCC) (Definition) |
Cellular injury by non-sensitized effector cells (monocytes, neutrophils, eosinophils, NK cells) in response to antibody binding to self-cells |
|
Clinical examples of antibody dependent cell-mediated cytotoxicity |
Tumor cell destruction
Parasite destruction
Allograft rejection |
|
Antibody-mediated cellular dysfunction (Definition) |
A disease caused by antibodies without cell injury or inflammation |
|
Clinical examples of antibody-mediated cellular dysfunction |
Myasthenia Gravis
Grave's disease |
|
Myasthenia Gravis (Mechanism, Symptoms) |
Antibodies directed against ACh receptors on motor end plates of skeletal muscle block ACh binding, resulting in muscle weakness |
|
Grave's disease (Mechanism) |
Antibodies directed against TSH receptor stimulate secretion of thyroid hormones and subsequent hyperthyroidism |
|
Like type I hypersensitivity, the severity of type II hypersensitivity is determined by ____ |
Antigen location |
|
Type III hypersensitivity (immune complex-mediated) (Definition) |
An immunologic reaction induced by Ag-Ab complexes that produce tissue damage as a result of their capacity to activate the complement system |
|
Immune complexes of what size are most pathogenic? |
Small or intermediate |
|
Why are small or intermediate immune complexes more pathogenic than large immune complexes? |
They are not as efficiently removed by phagocytic cells |
|
What conditions promote the formation of small or intermediate immune complexes? |
Slight antigen excess |
|
What are two potential causes of slight antigen excess? |
1) The antigen is a self-antigen
2) Underwhelming immune response |
|
Beyond antigen excess, what is another possible cause of an increase in immune complexes? |
Failure of the mononuclear phagocytic system to effectively eliminate immune complexes, whether due to dysfunction or overload |
|
Where are immune complexes most likely to deposit? |
Vascular filtration beds (glomerular basement membranes, synovial membranes, serosal surfaces, arachnoid granulations, lacrimal glands, and salivary glands) |
|
What are the three phases of systemic immune complex disease? |
1) Formation of Ag-Ab complexes in the circulation (5 days)
2) Deposition of the immune complexes in various tissues, facilitated by the increase in vascular permeability that occurs when cytokines are released by inflammatory cells after interaction with immune complexes via C3b or Fc receptors
3) Initiation of an inflammatory response in dispersed sites throughout the body (10 days) |
|
Examples of systemic immune complex diseases |
Acute and chronic serum sickness
Acute poststreptococcal glomerulonephritis
Systemic lupus erythematosus |
|
Why is it difficult to diagnose a specific systemic immune complex disease? |
They have overlapping symptoms |
|
Arthus reaction (Definition) |
A local immune complex disease that results from acute immune complex vasculitis |
|
How can an Arthus reaction be produced experimentally? |
Intracutaneous injection of an antigen in a subject that already has circulating antibodies to the injected antigen |
|
When does an Arthus reaction reach its peak? |
4 to 10 hours after antigen injection |
|
Unlike the other effector mechanisms of immune injury, type III hypersensitivity is not dependent on ____ |
Antigen location |
|
Type IV hypersensitivity (cell-mediated) (Definition) |
An immunological reaction initiated by specifically sensitized T lymphocytes; includes classic delayed-type hypersensitivity reactions initiated by helper T cells and direct cell cytotoxicity mediated by cytotoxic T cells |
|
In order for a delayed-type hypersensitivity reaction (type IV) to occur, an individual must be ____ to the antigen |
Sensitized |
|
What are the steps in a delayed-type hypersensitivity reaction (type IV)? |
1) Patient is re-exposed to antigen
2) Memory Th1 cells bind the antigen and secrete cytokines (e.g. IL-12, IFN-γ, IL-2, TNF-α)
3) Activated macrophages attempt to remove the offending antigen
4) Granulomas form |
|
What are some examples of delayed-type hypersensitivity reactions (type IV)? |
A positive tuberculin skin test
Cutaneous exposure to poison ivy or oak |
|
What is T cell-mediated cytotoxicity (Type IV)? |
The killing of antigen-bearing cells by sensitized cytotoxic T cells |
|
Cytokine storm (Definition) |
The systemic release of cytokines |
|
What can cause a cytokine storm? |
Severe physiological injury |
|
What are the effects of systemic cytokine release? |
Systemic vasodilation and subsequent hypotension
Widespread endothelial injury and activation, causing leukocyte adhesion and alveolar capillary damage
Activation of the coagulation pathway |
|
The various effects of a cytokine storm combine to cause... |
Widespread hypoperfusion that may lead to multisystem organ failure |